Skip to main content

Cladribine followed by autologous stem-cell transplantation in progressive multiple sclerosis

Buy Article:

$51.00 plus tax (Refund Policy)



We studied the safety of autologous peripheral blood stem-cell transplantation (PBSCT) in four patients with progressive multiple sclerosis. Clinical and magnetic resonance imaging outcomes were secondary end-points. Cladribine administration preceded filgrastim-primed PBSC collection, aiming for lymphocyte depletion. Conditioning was with antithymocyte globulin and cyclophosphamide. The procedure was well tolerated, but without obvious clinical benefit. The study was ­terminated when other therapeutic options with lower morbidity became available. (Intern Med J 2004; 34: 66−69)

Keywords: cladribine; stem-cell transplant;  multiple sclerosis

Document Type: Research Article


Affiliations: 1: Bone Marrow Transplant Service and Departments of 2: Neurosciences and 3: Radiology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.

Publication date: January 1, 2004

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more